Aquestive Therapeutics, Inc. (AQST) Ownership
AQST ownership summary
as of October 17, 2026- Institutions
- 57.8% of shares outstanding
- Insiders
- 10.76% of shares outstanding
- Shares outstanding
- 125.5M
- Float
- 113.1M shares available to trade
- Short interest
- 23.98% 28.7M shares short
- Days to cover
- 12.69 short interest up 5.8% vs prior month
- Institutions 57.82%
- Insiders 10.76%
- Other investors 31.42%
AQST top institutional holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | Bratton Capital Management, L.P. | 7.82% | 9.8M | $37.1M | — | June 30, 2026 |
| 2 | BlackRock Inc | 6.43% | 8.1M | $30.5M | +560,302 (+7.5%) | June 30, 2026 |
| 3 | RTW INVESTMENTS, LLC | 5.92% | 7.4M | $28.1M | — | June 30, 2026 |
| 4 | Vanguard Capital Management, LLC | 3.65% | 4.6M | $17.3M | +140,835 (+3.2%) | June 30, 2026 |
| 5 | Federated Hermes Inc | 2.48% | 3.1M | $11.8M | +172,222 (+5.9%) | June 30, 2026 |
| 6 | State Street Corp | 2.33% | 2.9M | $11.1M | +381,829 (+15.0%) | June 30, 2026 |
| 7 | Geode Capital Management, LLC | 2.09% | 2.6M | $9.9M | +214,697 (+8.9%) | June 30, 2026 |
| 8 | Samsara BioCapital, LLC | 1.99% | 2.5M | $9.4M | — | June 30, 2026 |
| 9 | Bank of America Corp | 1.33% | 1.7M | $6.3M | −736,627 (−30.6%) | June 30, 2026 |
| 10 | Sio Capital Management, LLC | 1.18% | 1.5M | $5.6M | −436,712 (−22.7%) | June 30, 2026 |
| 11 | Propel Bio Management LLC | 1.15% | 1.4M | $5.5M | +731,409 (+102.9%) | June 30, 2026 |
| 12 | Wasatch Advisors LP | 1.10% | 1.4M | $5.2M | +507,527 (+57.8%) | June 30, 2026 |
| 13 | Two Sigma Investments LLC | 1.02% | 1.3M | $4.8M | +141,823 (+12.4%) | June 30, 2026 |
| 14 | Nuveen, LLC | 0.97% | 1.2M | $4.6M | +961,760 (+379.4%) | June 30, 2026 |
| 15 | Janney Montgomery Scott LLC | 0.88% | 1.1M | $4.2M | +17,050 (+1.6%) | June 30, 2026 |
| 16 | Wells Fargo & Co | 0.87% | 1.1M | $4.1M | +54,393 (+5.3%) | June 30, 2026 |
| 17 | Commonwealth Equity Services, LLC | 0.83% | 1.0M | $4.0M | −36,505 (−3.4%) | June 30, 2026 |
| 18 | Barclays PLC | 0.79% | 997K | $3.8M | +197,502 (+24.7%) | June 30, 2026 |
| 19 | Blue Owl Capital Holdings LP | 0.75% | 943K | $3.6M | −405,000 (−30.0%) | June 30, 2026 |
| 20 | Northern Trust Corp | 0.66% | 831K | $3.1M | +98,647 (+13.5%) | June 30, 2026 |
Value at the latest close. Change = shares bought or sold in the latest quarterly filing (13F). In the top 20, 13 holders added 4.2M shares and 4 cut 1.6M.
AQST top mutual fund and ETF holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | Vanguard MStar Total Stk Mkt Idx Invest | 2.71% | 3.4M | $12.9M | — | August 31, 2026 |
| 2 | iShares Russell 2000 ETF | 2.26% | 2.8M | $10.7M | −32,640 (−1.1%) | September 30, 2026 |
| 3 | Federated Hermes MDT Small Cap Core IS | 1.11% | 1.4M | $5.3M | — | June 30, 2026 |
| 4 | State Street® SPDR® S&P® PhrmctlsETF | 1.05% | 1.3M | $5.0M | −16,320 (−1.2%) | September 30, 2026 |
| 5 | Fidelity Small Cap Index | 0.93% | 1.2M | $4.4M | +2,918 (+0.2%) | July 31, 2026 |
| 6 | Bridge Builder Small/Mid Cap Value | 0.61% | 765K | $2.9M | +733,908 (+2,397.9%) | September 30, 2026 |
| 7 | Wasatch Ultra Growth | 0.57% | 719K | $2.7M | −137,208 (−16.0%) | June 30, 2026 |
| 8 | iShares Russell 2000 Value ETF | 0.51% | 646K | $2.4M | +978 (+0.2%) | September 30, 2026 |
| 9 | Wasatch Micro Cap | 0.51% | 642K | $2.4M | +642,475 (0.0%) | June 30, 2026 |
| 10 | Vanguard Russell 2000 ETF | 0.49% | 621K | $2.3M | +14,215 (+2.3%) | August 31, 2026 |
| 11 | Federated Hermes MDT Small Cap Growth IS | 0.42% | 530K | $2.0M | +77,200 (+17.0%) | June 30, 2026 |
| 12 | Fidelity Extended Market Index | 0.37% | 466K | $1.8M | +5,465 (+1.2%) | August 31, 2026 |
| 13 | iShares Russell 2000 Growth ETF | 0.30% | 378K | $1.4M | −478 (−0.1%) | September 30, 2026 |
| 14 | iShares Micro-Cap ETF | 0.27% | 341K | $1.3M | −2,349 (−0.7%) | September 30, 2026 |
| 15 | Simplify Propel Opportunities ETF | 0.22% | 279K | $1.1M | — | September 30, 2026 |
| 16 | Federated Hermes MDT Small Cap Core ETF | 0.21% | 263K | $994,764 | −2,198 (−0.8%) | September 30, 2026 |
| 17 | Schwab Small Cap Index | 0.21% | 263K | $992,284 | — | August 31, 2026 |
| 18 | Stt Strt SPDR® Russell2000 US SmCapETF | 0.18% | 224K | $848,296 | +10,740 (+5.0%) | August 31, 2026 |
| 19 | Truvalue Glb Phrmctl Blgcl Eq (QDII) A | 0.17% | 210K | $793,275 | −310,445 (−59.7%) | June 30, 2026 |
| 20 | iShares Russell 2000 Small-Cap Idx Instl | 0.16% | 202K | $763,004 | — | August 31, 2026 |
Funds report holdings monthly or quarterly; dates differ by fund.
AQST insider transactions
latest 15| Date | Name | Transaction | Price | Shares | Value |
|---|---|---|---|---|---|
| 2026-03-10 | A Ernest Toth Jr | Sell | $4.17 | 58,254 | $242,919 |
| 2026-03-10 | Cassie Jung | Sell | $4.17 | 45,791 | $190,948 |
| 2026-03-10 | Daniel Barber | Sell | $4.17 | 180,677 | $753,423 |
| 2026-03-10 | Lori J Braender | Sell | $4.17 | 40,102 | $167,225 |
| 2026-03-10 | Melina Cioffi | Sell | $4.17 | 25,311 | $105,547 |
| 2026-03-10 | Peter E Boyd | Sell | $4.17 | 29,814 | $124,324 |
| 2026-03-10 | Sherry Korczynski | Sell | $4.17 | 15,741 | $65,640 |
| 2025-10-15 | Carl N Kraus | Sell | $7.00 | 20,272 | $141,904 |
| 2025-10-15 | Cassie Jung | Sell | $7.01 | 67,575 | $473,701 |
| 2025-10-15 | Peter E Boyd | Sell | $7.00 | 10,000 | $70,000 |
| 2025-09-26 | Daniel Barber | Sell | $6.03 | 91,343 | $550,798 |
| 2025-09-26 | Peter E Boyd | Sell | $6.30 | 10,000 | $63,000 |
| 2025-09-19 | Daniel Barber | Sell | $6.00 | 400 | $2,400 |
| 2025-09-05 | Peter E Boyd | Sell | $5.30 | 15,000 | $79,500 |
| 2025-09-04 | Cassie Jung | Sell | $5.00 | 62,180 | $310,900 |
Reported trades by company officers, directors and other filers (including disclosures by members of Congress where EODHD lists them). "—" where the filing gives no share count.
AQST shares outstanding
Year-end shares outstanding, adjusted for splits.
Who owns AQST
Institutional investors own 57.8% of Aquestive Therapeutics's shares and insiders 10.76%. The largest holder is Bratton Capital Management, L.P. with 7.82% of the shares (9.8M), as of June 30, 2026. Among the top 20 institutions, 13 added shares and 4 reduced their stake in the latest filings. Short interest is 23.98% of the float, or 12.69 days of average trading volume. The share count rose 687.9% since 2007.
Related: AQST analyst forecast, AQST key metrics. See the AQST stock overview for the latest quote and news.
AQST ownership FAQ
Who owns the most Aquestive Therapeutics stock?
The largest shareholders of Aquestive Therapeutics are Bratton Capital Management, L.P. (7.82%), BlackRock Inc (6.43%), RTW INVESTMENTS, LLC (5.92%), Vanguard Capital Management, LLC (3.65%), Federated Hermes Inc (2.48%).
What percentage of Aquestive Therapeutics is owned by institutions?
Institutions hold 57.8% of Aquestive Therapeutics's shares outstanding; insiders hold 10.76%.
Which funds own Aquestive Therapeutics?
The largest fund holders of Aquestive Therapeutics are Vanguard MStar Total Stk Mkt Idx Invest (2.71%), iShares Russell 2000 ETF (2.26%), Federated Hermes MDT Small Cap Core IS (1.11%), State Street® SPDR® S&P® PhrmctlsETF (1.05%), Fidelity Small Cap Index (0.93%).
What is Aquestive Therapeutics's short interest?
28.7M shares of Aquestive Therapeutics were sold short, 23.98% of the float; at the average daily volume it would take 12.69 days to cover.
Are insiders buying or selling Aquestive Therapeutics?
Of the latest 15 reported insider transactions in Aquestive Therapeutics (since September 4, 2025), 0 were purchases and 15 were sales.
How many shares of Aquestive Therapeutics are outstanding?
Aquestive Therapeutics has 125.5M shares outstanding, of which 113.1M are in the public float.